Patients with follicular lymphoma (FL) generally have favourable outcomes after receiving first-line immunochemotherapy; however, treatment options are limited for those with relapsed and/or refractory (R/R) disease, especially if they have high-risk disease. Now, data from the phase II TRANSCEND FL trial demonstrate the efficacy of the CD19-targeted chimeric antigen receptor (CAR) T cell product lisocabtagene maraleucel (liso-cel) in patients with R/R FL.

The ORR was 97% in patients receiving 3L+ liso-cel, including a complete response (CR) in 94% of them. In the 2L setting, 96% of patients had an objective response, all of which were CRs. At 12 months, the duration of response rate was 82% and 90% in patients receiving 3L+ and 2L liso-cel, respectively; progression-free survival was 81% and 91%; and overall survival was 92% and 96%. At a median follow-up duration of at least 16.6 months, the median duration for these end points was not reached in either group.

滤泡性淋巴瘤（FL）患者在接受一线免疫化疗后通常会获得良好的预后；然而，对于患有复发和/或难治性 (R/R) 疾病的患者，尤其是患有高风险疾病的患者，治疗选择有限。现在，II 期 TRANSCEND FL 试验的数据证明了靶向 CD19 的嵌合抗原受体 (CAR) T 细胞产品 lisocabtagene maraleucel (liso-cel) 对 R/R FL 患者的疗效。

接受 3L+ liso-cel 治疗的患者的 ORR 为 97%，其中 94% 达到完全缓解 (CR)。在 2L 治疗中，96% 的患者出现客观缓解，全部为 CR。 12 个月时，接受 3L+ 和 2L liso-cel 治疗的患者的缓解率持续时间分别为 82% 和 90%；无进展生存率分别为 81% 和 91%；总生存率分别为 92% 和 96%。在至少 16.6 个月的中位随访时间中，两组均未达到这些终点的中位持续时间。